Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia

NCT02269644 is registered in ClinicalTrials.gov with Durata Therapeutics Inc., an affiliate of Allergan plc as lead sponsor.

NCT NCT02269644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase
Phase 3
Overall status
Withdrawn
Start date
November 30, 2015
Completion date
December 31, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

community acquired pneumonia